There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Kasey Corripio |
| Institution: | University of Central Florida |
| Department: | Biomedical Sciences |
| Country: | |
| Proposed Analysis: | This study is part of an undergraduate honors in the major thesis at the University of Central Florida, to be completed under the supervision of Dr. Alicia Hawthorne through the summer of 2023. Associations between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) and the severity of cognitive impairment are unclear. In addition, more research is needed on the associations between CSF biomarkers of AD with Digital Cognitive Biomarkers (DCBs), which more closely measure underlying cognitive processes of encoding and retrieval. The presence of standard biomarkers, such as amyloid deposition, has been correlated with cognitive function [1]. However, reports from earlier investigations on the relationship between cognitive function and biomarkers have varied. While numerous previous research has identified an association between episodic memory and biometric marker concentrations, one study showed no correlation between biomarkers with several elements of cognition [2, 3]. By verifying whether cognitive performance measured by DCBs correlated with CSF biomarkers levels, we can understand the potential usefulness of DCB measures in primary and secondary levels of care. The specific objective of this study is to verify whether Digital Cognitive Biomarkers correlate with the AD classic CSF biomarkers Aβ42, T-tau, and p-tau levels in patients with varying levels of cognitive decline, as compared to cognitively healthy elderly populations (controls). We will test correlations between DCBs with CSF Aβ42, T-tau, p-tau, and Aβ42/p-tau. We predict our results will show that the cognitive processes of encoding and retrieval correlate with CSF biomarkers, which might prove more DCBs more robust and eventually become useful as supportive instruments in monitoring disease progression and response to therapeutic interventions. References 1. Duke Han, S., et al., Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis. Neuropsychology Review, 2017. 27(4): p. 305-325. 2. Ibarra, R., et al., AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State. Journal of Geriatric Psychiatry and Neurology, 2021. 34(6): p. 659-667. 3. Vemuri, P., et al., Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology, 2010. 75(2): p. 143. |
| Additional Investigators | |
| Investigator's Name: | Alicia Hawthorne |
| Proposed Analysis: | This study is part of an undergraduate honors in the major thesis at the University of Central Florida, to be completed under the supervision of Dr. Alicia Hawthorne through the summer of 2023. Associations between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) and the severity of cognitive impairment are unclear. In addition, more research is needed on the associations between CSF biomarkers of AD with Digital Cognitive Biomarkers (DCBs), which more closely measure underlying cognitive processes of encoding and retrieval. The presence of standard biomarkers, such as amyloid deposition, has been correlated with cognitive function [1]. However, reports from earlier investigations on the relationship between cognitive function and biomarkers have varied. While numerous previous research has identified an association between episodic memory and biometric marker concentrations, one study showed no correlation between biomarkers with several elements of cognition [2, 3]. By verifying whether cognitive performance measured by DCBs correlated with CSF biomarkers levels, we can understand the potential usefulness of DCB measures in primary and secondary levels of care. The specific objective of this study is to verify whether Digital Cognitive Biomarkers correlate with the AD classic CSF biomarkers Aβ42, T-tau, and p-tau levels in patients with varying levels of cognitive decline, as compared to cognitively healthy elderly populations (controls). We will test correlations between DCBs with CSF Aβ42, T-tau, p-tau, and Aβ42/p-tau. We predict our results will show that the cognitive processes of encoding and retrieval correlate with CSF biomarkers, which might prove more DCBs more robust and eventually become useful as supportive instruments in monitoring disease progression and response to therapeutic interventions. References 1. Duke Han, S., et al., Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis. Neuropsychology Review, 2017. 27(4): p. 305-325. 2. Ibarra, R., et al., AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State. Journal of Geriatric Psychiatry and Neurology, 2021. 34(6): p. 659-667. 3. Vemuri, P., et al., Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology, 2010. 75(2): p. 143. |
